Publications by authors named "Liga Kuksa"

Claim this Profile
A
Adverse drug reactions, particularly liver disorders, drive interruptions in anti-tuberculosis treatment: A retrospective cohort study.
Eleanor G Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Liga Kuksa

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.
Christoph Lange, Graham Bothamley, Gunar Günther, Lorenzo Guglielmetti, Irina Kontsevaya, Liga Kuksa

Pathog Immun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis.
Anthony J Garcia-Prats, Maria Garcia-Cremades, Vivian Cox, Tamara Kredo, Rory Dunbar, Liga Kuksa

Lancet Child Adolesc Health· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Oleksandr Korotych, Jay Achar, Elmira Gurbanova, Arax Hovhannesyan, Nino Lomtadze, Liga Kuksa

Lancet Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tuberculosis incidence in foreign-born people residing in European countries in 2020.
Anca Vasiliu, Niklas Köhler, Ekkehardt Altpeter, Tinna Rán Ægisdóttir, Marina Amerali, Liga Kuksa

Euro Surveill· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
Lorenzo Guglielmetti, Gunar Günther, Claude Leu, Daniela Cirillo, Raquel Duarte, Liga Kuksa

Eur Respir J· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.
Simone Hj van den Elsen, Marieke Gg Sturkenboom, Onno Akkerman, Linda Barkane, Judith Bruchfeld, Liga Kuksa

BMJ Open· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei, Linda Barkane, Andrea Benedetti, Liga Kuksa

Lancet Respir Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
Sergey Borisov, Edvardas Danila, Andrei Maryandyshev, Margareth Dalcolmo, Skaidrius Miliauskas, Liga Kuksa

Eur Respir J· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
Onno Akkerman, Alena Aleksa, Jan-Willem Alffenaar, Nada Hassan Al-Marzouqi, Miguel Arias-Guillén, Liga Kuksa

Int J Infect Dis· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
Frank van Leth, Folke Brinkmann, Daniela M Cirillo, Keertan Dheda, Raquel Duarte, Liga Kuksa

Eur Respir J· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Lancet· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
Lorenzo Guglielmetti, Linda Barkane, Damien Le Dû, Dhiba Marigot-Outtandy, Jérôme Robert, Liga Kuksa

Eur Respir J· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
Liga Kuksa, Linda Barkane, Norbert Hittel, Rajesh Gupta

Eur Respir J· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia.
Helen R Stagg, Peter J White, Vija Riekstiņa, Andra Cīrule, Ģirts Šķenders, Liga Kuksa

Emerg Infect Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.
J Peter Cegielski, Ekaterina Kurbatova, Martie van der Walt, Jeannette Brand, Julia Ershova, Liga Kuksa

Clin Infect Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.
J Peter Cegielski, Tracy Dalton, Martin Yagui, Wanpen Wattanaamornkiet, Grigory V Volchenkov, Liga Kuksa

Clin Infect Dis· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.
Christoph Lange, Ibrahim Abubakar, Jan-Willem C Alffenaar, Graham Bothamley, Jose A Caminero, Liga Kuksa

Eur Respir J· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.
Tracy Dalton, Peter Cegielski, Somsak Akksilp, Luis Asencios, Janice Campos Caoili, Liga Kuksa

Lancet· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis